Effect of Periodontal Treatment on the Crevicular Level of High-mobility Group Box 1 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Patients with Chronic Periodontitis
AbstractThe present study aimed to compare the levels of high-mobility group box 1(HMGB1) and soluble triggering receptor expressed on myeloid cells (sTREM1) in the gingival crevicular fluid (GCF). This cross-sectional cohort trial investigated two groups of 22 eligible chronic periodontitis and 22 periodontally healthy individuals (student volunteers) both before and after the periodontal treatment. GCF was collected from the deepest pockets with clinical attachment loss≥3 mm. Both groups received oral hygiene instructions, and scaling and root planning were performed in the test group. Enzyme-linked immunosorbent assay kit (ELISA) was used to measure the levels of HMGB1 and sTREM1 in GCF samples collected before and 1 month after non-surgical periodontal treatment. The results showed that HMGB1 levels were significantly higher in the chronic periodontitis patients than those of the healthy individuals before treatment (p<0.02) and decreased significantly after periodontal treatment, which reduced gingival inflammation. Furthermore, the levels of sTREM1 marker were significantly higher in periodontitis patients before (p<0.001) and 1 month after treatment than in healthy individuals (p<0.003) although its crevicular levels decreased after periodontal therapy in periodontitis group. The higher levels of sTREM1 and HMGB1 cytokines in GCF of periodontitis patients and the significant decrease after the introduction of the periodontal treatment underlines the importance of HMGB1 and sTREM1 in pathogenesis of periodontitis.
1. Graves D. Cytokines that promote periodontal tissue destruction. J Periodontol. 2008; 79(8 Suppl):1585-91.2. Barros SP, Williams R, Offenbacher S, Morelli T. Gingival crevicular fluid as a source of biomarkers for periodontitis. Periodontology 2000. 2016; 70(1):53-64.3. Chitanuwat A, Laosrisin N, Dhanesuan N. Role of HMGB1 in proliferation and migration of human gingival and periodontal ligament fibroblasts. J Oral Sci 2013; 55(1):45-50.4. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285(5425):248-51.5. McMahon L, Schwartz K, Yilmaz O, Brown E, Ryan LK, Diamond G. Vitamin D-mediated induction of innate immunity in gingival epithelial cells. Infect Immun 2011; 79(6):2250-6.6. Gibot S. Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis. Crit Care 2005; 9(5):485-9.7. Slotwinski R, Sarnecka A, Dabrowska A, Kosalka K, Wachowska E, Balan BJ, et al. Innate immunity gene expression changes in critically ill patients with sepsis and disease-related malnutrition. Cent Eur J Immuno 2015; 40(3):311-24.8. Determann RM, Millo JL, Gibot S, Korevaar JC, Vroom MB, van der Poll T, et al. Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia. Intensive Care Med 2005; 31(11):1495-500.9. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003; 48(4):971-81.10. Bostanci N, Thurnheer T, Aduse-Opoku J, Curtis MA, Zinkernagel AS, Belibasakis GN. Porphyromonas gingivalis regulates TREM-1 in human polymorphonuclear neutrophils via its gingipains. PLoS One 2013; 8(10):e75784.11. Bostanci N, Thurnheer T, Belibasakis GN. Involvement of the TREM-1/DAP12 pathway in the innate immune responses to Porphyromonas gingivalis. Mol Immunol 2011; 49(1-2):387-94.12. Paknejad M, Sattari M, Roozbahani Z, Ershadi M, Mehrfard A. Relationships between High-mobility Group Protein B1 and Triggering Receptor Expressed on Myeloid Cells Concentrations in Gingival Crevicular Fluid and Chronic Periodontitis. Iran J Allergy Asthma Immunol 2016; 15(5):381-5.13. Armitage GC. Periodontal diagnoses and classification of periodontal diseases. Periodontol 2000 2004; 34:9-21.14. Kadkhoda Z, Amirzargar A, Esmaili Z, Vojdanian M, Akbari S. Effect of TNF-alpha Blockade in Gingival Crevicular Fluid on Periodontal Condition of Patients with Rheumatoid Arthritis. Iranian journal of immunology : Iran J Allergy Asthma Immunol 2016; 13(3):197-203.15. Luo L, Xie P, Gong P, Tang XH, Ding Y, Deng LX. Expression of HMGB1 and HMGN2 in gingival tissues, GCF and PICF of periodontitis patients and peri-implantitis. Arch Oral Biol 2011; 56(10):1106-11.16. Hasegawa N. [Effect of high mobility group box 1 (HMGB1) in cultured human periodontal ligament cells]. Kokubyo Gakkai zasshi 2008; 75(3):155-61.17. Ek M, Popovic K, Harris HE, Naucler CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006; 54(7):2289-94.18. Chen G, Li J, Qiang X, Czura CJ, Ochani M, Ochani K, et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 2005; 46(4):623-7.19. Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, et al. HMGB1 in health and disease. Mol Aspects Med 2014; 40:1-116.20. Morimoto Y, Kawahara KI, Tancharoen S, Kikuchi K, Matsuyama T, Hashiguchi T, et al. Tumor necrosis factor-alpha stimulates gingival epithelial cells to release high mobility-group box 1. J Periodontal Res 2008; 43(1):76-83.21. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004; 24(12):2320-5.22. Colonna M, Facchetti F. TREM-1 (triggering receptor expressed on myeloid cells): a new player in acute inflammatory responses. J Infect Dis 2003; 187 Suppl 2:S397-401.23. Gibot S, Massin F. Soluble form of the triggering receptor expressed on myeloid cells 1: an anti-inflammatory mediator? Intensive Care Med 2006; 32(2):185-7.24. Dimopoulou I, Pelekanou A, Mavrou I, Savva A, Tzanela M, Kotsaki A, et al. Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: correlation with monocyte gene expression. J Crit Care 2012; 27(3):294-300.25. Gibot S, Cravoisy A. Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. Clin Med Res 2004; 2(3):181-7.26. Bisson C, Massin F, Lefevre PA, Thilly N, Miller N, Gibot S. Increased gingival crevicular fluid levels of soluble triggering receptor expressed on myeloid cells (sTREM) -1 in severe periodontitis. J Clin Periodontol 2012; 39(12):1141-8.27. Belibasakis GN, Ozturk VO, Emingil G, Bostanci N. Soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) in gingival crevicular fluid: association with clinical and microbiologic parameters. J Periodontol 2014; 85(1):204-10.28. Bostanci N, Ozturk VO, Emingil G, Belibasakis GN. Elevated oral and systemic levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in periodontitis. J Dent Res 2013; 92(2):161-5.